{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:35:33Z","timestamp":1784345733904,"version":"3.55.0"},"reference-count":40,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Retinal dystrophies linked to the RPE65 gene are mostly fast-progressing retinal diseases, with childhood onset of night blindness and progressive visual loss up to the middle adult age. Rare phenotypes linked to this gene are known with congenital stationary night blindness or slowly progressing retinitis pigmentosa, as well as an autosomal dominant c.1430A&gt;G (p.Asp477Gly) variant. This review gives an overview of the current knowledge of the clinical phenotypes, as well as experience with the efficacy and safety of the approved gene augmentation therapy voretigene neparvovec.<\/jats:p>","DOI":"10.1055\/a-2227-3671","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T23:55:08Z","timestamp":1710978908000},"page":"259-265","source":"Crossref","is-referenced-by-count":6,"title":["RPE65-Associated Retinal Dystrophies: Phenotypes and Treatment Effects with Voretigene Neparvovec"],"prefix":"10.1055","volume":"241","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8132-911X","authenticated-orcid":false,"given":"Katarina","family":"Stingl","sequence":"first","affiliation":[{"name":"University Eye Hospital, Center for Ophthalmology, University of T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1847-3626","authenticated-orcid":false,"given":"Claudia","family":"Priglinger","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Ludwig-Maximilians-University Hospital, LMU Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Herrmann","sequence":"additional","affiliation":[{"name":"University Eye Hospital Bonn, University Hospital Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"15751","DOI":"10.1016\/S0021-9258(18)82319-5","article-title":"Molecular cloning and expression of RPE65, a novel retinal pigment epithelium-specific microsomal protein that is post-transcriptionally regulated in vitro","volume":"268","author":"C P Hamel","year":"1993","journal-title":"J Biol Chem"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/hmg\/4.4.641","article-title":"Molecular characterization of the human gene encoding an abundant 61\u2009kDa protein specific to the retinal pigment epithelium","volume":"4","author":"A Nicoletti","year":"1995","journal-title":"Hum Mol Genet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"101013","DOI":"10.1016\/j.preteyeres.2021.101013","article-title":"Retinal pigment epithelium 65\u2009kDa protein (RPE65): An update","volume":"88","author":"P D Kiser","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/ng1097-194","article-title":"Mutations in RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy","volume":"17","author":"S M Gu","year":"1997","journal-title":"Nat Genet"},{"key":"ref5","first-page":"4293","article-title":"Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration","volume":"41","author":"D A Thompson","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.preteyeres.2018.03.005","article-title":"Non-syndromic retinitis pigmentosa","volume":"66","author":"S K Verbakel","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/archopht.120.1.55","article-title":"Clinical course and visual function in a family with mutations in the RPE65 gene","volume":"120","author":"J Felius","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1136\/bjophthalmol-2015-308019","article-title":"Preserved visual function in retinal dystrophy due to hypomorphic RPE65 mutations","volume":"100","author":"S Hull","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"ref9","first-page":"626","article-title":"The clinical features of retinal disease due to a dominant mutation in RPE65","volume":"22","author":"S Hull","year":"2016","journal-title":"Mol Vis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1167\/iovs.07-1671","article-title":"A comprehensive clinical and biochemical functional study of a novel RPE65 hypomorphic mutation","volume":"49","author":"B Lorenz","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.ophtha.2010.09.005","article-title":"Fundus albipunctatus associated with compound heterozygous mutations in RPE65","volume":"118","author":"P Schatz","year":"2011","journal-title":"Ophthalmology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/genes11121420","article-title":"Properties and Therapeutic Implications of an Enigmatic D477\u2009G RPE65 Variant Associated with Autosomal Dominant Retinitis Pigmentosa","volume":"11","author":"A S Kiang","year":"2020","journal-title":"Genes (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3\u2009Trials","volume":"126","author":"A M Maguire","year":"2019","journal-title":"Ophthalmology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"S Russell","year":"2017","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ajo.2018.09.024","article-title":"The Natural History of Inherited Retinal Dystrophy Due to Biallelic Mutations in the RPE65 Gene","volume":"199","author":"D C Chung","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1167\/iovs.08-2696","article-title":"Defining the residual vision in leber congenital amaurosis caused by RPE65 mutations","volume":"50","author":"S G Jacobson","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1167\/iovs.08-2121","article-title":"Photoreceptor layer topography in children with leber congenital amaurosis caused by RPE65 mutations","volume":"49","author":"S G Jacobson","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00417-004-1020-x","article-title":"Longitudinal and cross-sectional study of patients with early-onset severe retinal dystrophy associated with RPE65 mutations","volume":"243","author":"K Paunescu","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1167\/iovs.63.2.13","article-title":"RPE65-Associated Retinopathies in the Italian Population: A Longitudinal Natural History Study","volume":"63","author":"F Testa","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1073\/pnas.0500646102","article-title":"Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success","volume":"102","author":"S G Jacobson","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.ophtha.2004.01.033","article-title":"Lack of fundus autofluorescence to 488 nanometers from childhood on in patients with early-onset severe retinal dystrophy associated with mutations in RPE65","volume":"111","author":"B Lorenz","year":"2004","journal-title":"Ophthalmology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1167\/iovs.05-0965","article-title":"RPE65 gene delivery restores isomerohydrolase activity and prevents early cone loss in Rpe65-\/- mice","volume":"47","author":"Y Chen","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"13658","DOI":"10.1073\/pnas.0504167102","article-title":"Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle","volume":"102","author":"T M Redmond","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"a004952","DOI":"10.1101\/mcs.a004952","article-title":"Phenotypic expansion of autosomal dominant retinitis pigmentosa associated with the D477\u2009G mutation in RPE65","volume":"6","author":"R Jauregui","year":"2020","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1080\/13816810.2018.1484929","article-title":"Two-year progression analysis of RPE65 autosomal dominant retinitis pigmentosa","volume":"39","author":"R Jauregui","year":"2018","journal-title":"Ophthalmic Genet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/bjophthalmol-2020-318286","article-title":"Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec","volume":"106","author":"K Stingl","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ophtha.2023.02.015","article-title":"Full-field Scotopic Threshold Improvement after Voretigene Neparvovec-rzyl Treatment Correlates with Chorioretinal Atrophy","volume":"130","author":"K Stingl","year":"2023","journal-title":"Ophthalmology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"101115","DOI":"10.1016\/j.preteyeres.2022.101115","article-title":"Therapy with voretigene neparvovec. How to measure success?","volume":"92","author":"K Stingl","year":"2023","journal-title":"Prog Retin Eye Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.exer.2004.09.008","article-title":"Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures","volume":"80","author":"A J Roman","year":"2005","journal-title":"Exp Eye Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber\u02bcs congenital amaurosis","volume":"358","author":"A M Maguire","year":"2008","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ophtha.2012.11.048","article-title":"Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2","volume":"120","author":"F Testa","year":"2013","journal-title":"Ophthalmology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","article-title":"Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial","volume":"388","author":"J Bennett","year":"2016","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s15006-022-0765-7","article-title":"[RPE65-associated retinal dystrophies: gene therapy preserves vision]","volume":"164","author":"M J Gerhardt","year":"2022","journal-title":"MMW Fortschr Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ophtha.2016.03.003","article-title":"Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy","volume":"123","author":"R G Weleber","year":"2016","journal-title":"Ophthalmology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e2038","DOI":"10.1002\/mgg3.2038","article-title":"Chorioretinal atrophy following voretigene neparvovec despite the presence of fundus autofluorescence","volume":"10","author":"M Kolesnikova","year":"2022","journal-title":"Mol Genet Genomic Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1001\/jamaophthalmol.2020.2018","article-title":"Quantitative Autofluorescence Following Gene Therapy With Voretigene Neparvovec","volume":"138","author":"S R Levi","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1111\/aos.14990","article-title":"Short term morphological rescue of the fovea after gene therapy with voretigene neparvovec","volume":"100","author":"F C Kortum","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1136\/bjo-2022-321488","article-title":"Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy","volume":"107","author":"J Lopez","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","article-title":"Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis","volume":"6","author":"W S Gange","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/bjophthalmol-2021-321023","article-title":"Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec","volume":"107","author":"F F Reichel","year":"2023","journal-title":"Br J Ophthalmol"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2227-3671.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:04:03Z","timestamp":1737590643000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2227-3671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":40,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,3,20]]},"published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2227-3671","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}